Difference between revisions of "Team:Freiburg/Description"

Line 7: Line 7:
 
<h1>Description</h1>
 
<h1>Description</h1>
  
<p>Tell us about your project, describe what moves you and why this is something important for your team.</p>
 
  
 
<h5>What should this page contain?</h5>
 
<ul>
 
<li> A clear and concise description of your project.</li>
 
<li>A detailed explanation of why your team chose to work on this particular project.</li>
 
<li>References and sources to document your research.</li>
 
<li>Use illustrations and other visual resources to explain your project.</li>
 
</ul>
 
  
  
Line 44: Line 35:
 
</p>
 
</p>
  
 
 
</div>
 
 
 
<div class="column half_size" >
 
 
<h5>References</h5>
 
<p>iGEM teams are encouraged to record references you use during the course of your research. They should be posted somewhere on your wiki so that judges and other visitors can see how you thought about your project and what works inspired you.</p>
 
 
</div>
 
 
 
<div class="column half_size" >
 
<h5>Inspiration</h5>
 
<p>See how other teams have described and presented their projects: </p>
 
 
<ul>
 
<li><a href="https://2016.igem.org/Team:Imperial_College/Description">2016 Imperial College</a></li>
 
<li><a href="https://2016.igem.org/Team:Wageningen_UR/Description">2016 Wageningen UR</a></li>
 
<li><a href="https://2014.igem.org/Team:UC_Davis/Project_Overview"> 2014 UC Davis</a></li>
 
<li><a href="https://2014.igem.org/Team:SYSU-Software/Overview">2014 SYSU Software</a></li>
 
</ul>
 
</div>
 
  
  
  
 
</html>
 
</html>

Revision as of 15:52, 28 June 2017

Freiburg

Description

Advice on writing your Project Description

The treatment and understanding of cancer is a challenging issue. New approaches like the chimeric antigen receptor (CAR) T-cells showed promising results in fighting cancer by enhancing the killing effects of cytotoxic T-cells. The main benefit of CAR T-cells is their high affinity to tumor antigens, however this raises the issue of possible off-target effects since tumor antigens are not solely expressed on tumor cells but also on healthy tissues (Fesnak et al. 2016; Morgan et al. 2010). In order to avoid off-target effects, we aim to establish CAR T-cell lines which are only activated in the specific tumor microenvironment (Hanahan, Coussens 2012). The T-cells are modified to express CAR controlled by a genetic AND-gate system which needs two inputs from the tumor microenvironment to be activated. This would allow a highly localization restricted binding of cytotoxic T-cells to tumor cells and provide safer cancer cell-based immunotherapy.